Comparing the therapeutic index between newly diagnosed CML- patient- and healthy-donor-derived CD34+ cells, the authors identify VEGFR, MDM2, WEE1 inhibitors, and Mepacrine as selective inhibitors of CML-derived CD34+ cells. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.